AIM ImmunoTech Files Definitive Proxy Statement
Ticker: AIM · Form: DEF 14A · Filed: Apr 2, 2025 · CIK: 946644
Sentiment: neutral
Topics: proxy-statement, governance, shareholder-meeting
TL;DR
AIM ImmunoTech filed its proxy statement for a special meeting - shareholders vote soon.
AI Summary
AIM ImmunoTech Inc. filed a definitive proxy statement (DEF 14A) on April 2, 2025, for its special meeting of stockholders. The filing details information related to the company's governance and shareholder matters, including the election of directors and other corporate actions. The company is based in Ocala, Florida, and operates in the biological products sector.
Why It Matters
This filing provides shareholders with crucial information needed to make informed decisions regarding company leadership and important corporate proposals at the upcoming special meeting.
Risk Assessment
Risk Level: medium — Proxy statements often precede significant corporate events or shareholder votes that can impact stock price.
Key Players & Entities
- AIM ImmunoTech Inc. (company) — Registrant
- 0001641172-25-002408 (filing_id) — Accession Number
- 20250402 (date) — Filing Date
- 2117 SW Highway 484 Ocala FL 34473 (address) — Company Address
FAQ
What is the purpose of this DEF 14A filing?
The purpose of this DEF 14A filing is to provide shareholders with information for a special meeting, including details for the election of directors and other corporate actions.
When was this filing submitted to the SEC?
This filing was submitted to the SEC on April 2, 2025.
What is the company's primary business sector?
AIM ImmunoTech Inc. operates in the BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) sector, SIC code 2836.
Where is AIM ImmunoTech Inc. located?
AIM ImmunoTech Inc. is located at 2117 SW Highway 484, Ocala, FL 34473.
What is the filing type and SEC file number for this document?
The filing type is DEF 14A, and the SEC file number is 001-27072.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 2, 2025 regarding AIM ImmunoTech Inc. (AIM).